Effects of dabigatran: A Synthesis of Findings from 26 Studies

  1. Home
  2. Effects of dabigatran
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of dabigatran: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of dabigatran: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Dabigatran is a direct thrombin inhibitor that has been shown to be effective in preventing blood clots in patients with atrial fibrillation and other conditions. 5 . It is considered a safer alternative to warfarin, the traditional anticoagulant, with a lower risk of bleeding, especially intracranial bleeding. 5 . However, dabigatran has been associated with a higher risk of gastrointestinal bleeding compared to warfarin. 5 . Additionally, research suggests that dabigatran may help reduce the severity of stroke in patients with atrial fibrillation. 24 . Dabigatran does not interfere with vitamin K metabolism, making it a better choice for patients with concerns about bone health compared to warfarin. 25 . It has also been shown to be effective in the treatment of severe respiratory diseases, potentially offering an alternative therapy for asthma and COPD. 22 . Furthermore, dabigatran's stable anticoagulation properties make it a suitable option for atrial fibrillation ablation procedures. 19 .

Benefits and risks

Benefit summary

Dabigatran has been shown to be effective in preventing blood clots in patients with atrial fibrillation and other conditions. 5 . It is considered a safer alternative to warfarin, the traditional anticoagulant, with a lower risk of bleeding, especially intracranial bleeding. 5 . It may help reduce the severity of stroke in patients with atrial fibrillation. 24 . Dabigatran does not interfere with vitamin K metabolism, making it a better choice for patients with concerns about bone health compared to warfarin. 25 . It has also been shown to be effective in the treatment of severe respiratory diseases, potentially offering an alternative therapy for asthma and COPD. 22 . Furthermore, dabigatran's stable anticoagulation properties make it a suitable option for atrial fibrillation ablation procedures. 19 .

Risk summary

Dabigatran has been associated with a higher risk of gastrointestinal bleeding compared to warfarin. 5 .

Comparison across studies

Commonalities

Several studies have consistently demonstrated that dabigatran is effective in preventing blood clots in patients with atrial fibrillation. 5 24 19 .

Differences

Although some studies show that dabigatran is associated with a lower risk of overall bleeding compared to warfarin, findings regarding the risk of gastrointestinal bleeding are not entirely consistent across studies. 5 20 .

Consistency and contradictions of findings

While dabigatran consistently demonstrates effectiveness in preventing blood clots, the evidence regarding its risk profile, specifically for gastrointestinal bleeding, is mixed. 5 20 .

Practical considerations

Dabigatran offers a potential advantage over warfarin for stroke prevention, but its risk of gastrointestinal bleeding should be carefully considered. 5 . It is important to consult with your doctor to weigh the benefits and risks of dabigatran and determine if it is an appropriate treatment option for you. 5 . 26 .

Limitations of current research

Despite the growing body of research on dabigatran, there is still a need for further investigation. The long-term effects of dabigatran remain uncertain and require more extensive study. 1 . The impact of dabigatran on the resolution of left atrial appendage thrombi also requires further research. 8 .

Future research directions

Further studies are necessary to understand the long-term effects of dabigatran on the cardiovascular system, including its risk profile for gastrointestinal bleeding. 5 26 . Additionally, research on the impact of dabigatran on cognitive outcomes is needed. 12 . Further evaluation of dabigatran's role in the resolution of left atrial appendage thrombi would provide valuable insights. 8 .

Conclusion

Dabigatran has emerged as a promising anticoagulant with potential benefits in stroke prevention and overall safety compared to warfarin. 5 1 . However, its higher risk of gastrointestinal bleeding compared to warfarin should be carefully considered. 5 26 . Ongoing research will continue to refine our understanding of dabigatran's safety profile and its role in various medical scenarios. Consult with your doctor to determine if dabigatran is the appropriate anticoagulant for you. 5 .

Literature analysis of 26 papers
Positive Content
25
Neutral Content
1
Negative Content
0
Article Type
11
2
2
3
26
1.

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.

Author: DienerHans-Christoph, ConnollyStuart J, EzekowitzMichael D, WallentinLars, ReillyPaul A, YangSean, XavierDenis, Di PasqualeGiuseppe, YusufSalim,

Haemorrhage reduction
Stroke prevention

This study assessed the effects of dabigatran compared with warfarin in patients with atrial fibrillation who had previously experienced a stroke or transient ischemic attack.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.

Author: FriedmanRichard J, KurthAndreas, ClemensAndreas, NoackHerbert, ErikssonBengt I, CapriniJoseph A

Bleeding risk reduction
Thromboprophylaxis

This study assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?

Author: DaleBrian, EikelboomJohn W, WeitzJeffrey I, YoungEd, PaikinJeremy S, CoppensMichiel, WhitlockRichard P, ConnollyStuart J, GinsbergJeffrey S, HirshJack

Less intracranial hemorrhage
Increased risk of myocardial infarction

Dabigatran, a newer blood thinner, is associated with less intracranial bleeding compared to warfarin, but it also carries a higher risk of myocardial infarction. This study found that warfarin suppresses thrombin generation more effectively than dabigatran, potentially explaining the differences in these side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.

Author: SairakuAkinori, YoshidaYukihiko, AndoMonami, HirayamaHaruo, NakanoYukiko, KiharaYasuki

No need for anticoagulation monitoring
Increased risk of hypercoagulability

Rivaroxaban may increase the risk of hypercoagulability when used during the periprocedural period of atrial fibrillation (AF) ablation compared with dabigatran.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.

Author: BloomBenjamin J, FilionKristian B, AtallahRenée, EisenbergMark J

Bleeding risk reduction
Gastrointestinal bleeding

This meta-analysis of five randomized controlled trials (RCTs) compared the risk of bleeding and all-cause mortality of dabigatran with that of vitamin K antagonists (VKAs) in patients with atrial fibrillation and venous thromboembolism. The results suggest that dabigatran is not associated with an increased risk of major bleeding compared with VKAs. Dabigatran was associated with a decreased risk of intracranial bleeding but an increased risk of gastrointestinal bleeding. Dabigatran was also associated with a trend toward decreased all-cause mortality.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty.

Author: GombárCsaba, HorvathGyöngyi, GálityHristifor, SisákKrisztián, TóthKálmán

THR prophylaxis
Minor bleeding
Soft-tissue effects

This study compared the incidence of minor hemorrhagic and soft-tissue adverse effects of dabigatran etexilate and enoxaparin, two orally administered chemical thromboprophylactic agents for total hip replacement (THR).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.

Author: SardarPartha, NairoozRamez, ChatterjeeSaurav, WetterslevJørn, GhoshJoydeep, AronowWilbert S

AF ablation anticoagulation
Reduced minor bleeding
Stroke
TIA
Thromboembolic complications

Dabigatran, a novel oral anticoagulant, is sometimes used for thromboembolic prevention during atrial fibrillation (AF) ablation. This meta-analysis of 17 observational studies and 1 randomized trial showed that periprocedural dabigatran use was associated with a higher risk of thromboembolic complications, including stroke, compared to warfarin. Dabigatran showed a lower risk of minor bleeding compared to warfarin.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.

Author: FernerMarion, WachtlinDaniel, KonradTorsten, DeusterOliver, MeinertzThomas, von BardelebenStephan, MünzelThomas, Seibert-GrafeMonika, BreithardtGünter, RostockThomas

Thromboembolism prevention

Dabigatran etexilate is an effective oral anticoagulant for the prevention of thromboembolic events in patients with atrial fibrillation. However, there is limited evidence on its efficacy and safety for the resolution of left atrial appendage thrombi.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Dabigatran etexilate and reduction in serum apolipoprotein B.

Author: JosephPhilip, PareGuillaume, WallentinLars, ConnollyStuart, YusufSalim, WangJia, EzekowitzMichael, EikelboomJohn, SiegbahnAgneta, ReillyPaul, ThemelesEllison, OldgrenJonas,

Anticoagulation therapy

This study investigated the effects of dabigatran etexilate on serum lipoprotein markers in patients participating in the RE-LY study.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.

Author: FranchiFrancesco, RolliniFabiana, ChoJung Rae, KingRhodri, PhoenixFladia, BhattiMona, DeGroatChristopher, Tello-MontoliuAntonio, ZenniMartin M, GuzmanLuis A, BassTheodore A, AjjanRamzi A, AngiolilloDominick J

Favorable efficacy
Favorable safety
Delayed fibrin clot formation
Increased thrombin activity

In patients on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, adjunctive dabigatran therapy did not affect platelet reactivity but significantly increased parameters related to thrombin activity and delayed fibrin clot formation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

11.

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Author: SamuelsonBethany T, CukerAdam, SiegalDeborah M, CrowtherMark, GarciaDavid A

Treatment of choice for atrial fibrillation
Treatment of choice for venous thromboembolic disease

Direct oral anticoagulants (DOACs) are the treatment of choice for most patients with atrial fibrillation and/or noncancer-associated venous thromboembolic disease. This review summarizes systematically evidence regarding laboratory assessment of the anticoagulant effects of dabigatran, rivaroxaban, apixaban, and edoxaban.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

12.

Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial.

Author: CaramelliBruno, YuPai Ching, CardozoFrancisco A M, MagalhãesIuri R, SperaRaphael R, AmadoDaniel K, Escalante-RojasMaria C, GualandroDanielle M, CalderaroDaniela, TavaresCaio A M, Borges-JuniorFlavio A, PastanaAdriana F, MatheusMariana G, BruckiSonia M D, RodriguesAna Carolina O, NitriniRicardo, CaramelliPaulo

Dementia prevention

Dabigatran is a newer blood thinner that may reduce cognitive decline in older patients with atrial fibrillation compared to warfarin. While observational studies suggest a benefit, conclusive data are still lacking.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study.

Author: YasakaMasahiro, YokotaHiroyuki, SuzukiMichiyasu, AsakuraHidesaku, YamaneTeiichi, OgiYukako, KimotoTakaaki, NakayamaDaisuke

Reverses dabigatran effects

Idarucizumab is a monoclonal antibody fragment that rapidly reverses the anticoagulant effects of dabigatran. This study reports the final results of a postmarketing surveillance study that collected data on idarucizumab in Japanese patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.

Author: LindahlTomas L, BaghaeiFariba, BlixterInger Fagerberg, GustafssonKerstin M, StigendalLennart, Sten-LinderMargareta, StrandbergKarin, HillarpAndreas,

Thrombin inhibition
Bleeding risk

Dabigatran is a new oral anticoagulant. This study investigated the effects of dabigatran on common coagulation assays.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Effects of dabigatran according to age in atrial fibrillation.

Author: LauwMandy N, EikelboomJohn W, CoppensMichiel, WallentinLars, YusufSalim, EzekowitzMichael, OldgrenJonas, NakamyaJuliet, WangJia, ConnollyStuart J

Stroke prevention
Bleeding
Mortality

This study analyzed the effects of dabigatran versus warfarin on stroke, bleeding, and mortality in patients with atrial fibrillation across different age groups. The findings show that dabigatran may offer advantages over warfarin in older patients with atrial fibrillation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

17.

"Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan.

Author: SuzukiShinya, SagaraKoichi, OtsukaTakayuki, KanoHiroto, MatsunoShunsuke, TakaiHideaki, UejimaTokuhisa, OikawaYuji, KoikeAkira, NagashimaKazuyuki, KirigayaHajime, YajimaJunji, TanabeHiroaki, SawadaHitoshi, AizawaTadanori, YamashitaTakeshi

Dabigatran use caution

A safety advisory for dabigatran led to changes in physicians' attitudes towards prescribing, with a tendency to avoid use in older patients with renal dysfunction. However, attitudes shifted back towards increased use in these groups after permission for longer-term prescriptions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

18.

Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy.

Author: Aydin OzturkPınar, YilmazTevfik, OzturkUnal

Cerebral ischemia treatment
Restenosis
Spontaneous thrombosis

Dabigatran etexilate, a direct thrombin inhibitor, showed similar efficacy to bemiparin sodium, a second-generation low-molecular-weight heparin, in preventing thrombosis after carotid artery anastomosis.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation.

Author: OsawaTakumi, MoriHitoshi, KawaiAkane, KawanoDaisuke, TsutsuiKenta, IkedaYoshifumi, YamagaMitsuki, SatoAtsushi, GatateYoudou, HamabeAkira, TabataHirotsugu, KatoRitsushi, MatsumotoKazuo

Improved procedure outcomes
Stable anticoagulation

Uninterrupted dabigatran during atrial fibrillation (AF) ablation is useful for obtaining a stable anticoagulation status throughout the procedure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study.

Author: KikuchiShinnosuke, TsukaharaKengo, SakamakiKentaro, MoritaYukiko, TakamuraTakeshi, FukuiKazuki, EndoTsutomu, ShimizuMakoto, SawadaReimin, SuganoTeruyasu, HimenoHideo, KobayashiSyunichi, ArakawaKentaro, MochidaYasuyuki, TsunematsuTakashi, ShigemasaTomohiko, OkudaJun, IshikawaToshiyuki, KimuraKazuo, TamuraKouichi

Anti-inflammatory effects
Bleeding events

This study found no significant differences in the interval changes of inflammatory markers between rivaroxaban and dabigatran treatments in patients with atrial fibrillation. However, increased levels of soluble thrombomodulin (sTM) after DOAC treatment were associated with bleeding events.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

21.

Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.

Author: HoffmanMaureane, VolovykZoya, MonroeDougald M

Dabigatran reversal

Prothrombin complex concentrate (PCC) is more effective than recombinant factor VIIa (FVIIa) in reversing dabigatran anticoagulation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

22.

[Inhibitory Effects of Dabigatran on Airway Inflammation Induced by Lipopolysaccharide in Mice].

Author: KimuraGenki, TakahashiRisa, NagamotoAyaka, YoshinoKotomi, UedaKeitaro, NishimotoYuki, KizawaYasuo

Airway inflammation inhibition

This study investigates the effects of anti-coagulants on lipopolysaccharide (LPS)-induced airway inflammation in mice. The results suggest that dabigatran, a direct thrombin inhibitor, could be a potential new therapy for severe respiratory diseases like asthma and COPD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

23.

Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.

Author: HonickelMarkus, BraunschweigTill, van RynJoanne, Ten CateHugo, SpronkHenri M H, RossaintRolf, GrottkeOliver

Dabigatran reversal

This study investigated four-factor prothrombin complex concentrate (PCC) for treating dabigatran-induced anticoagulation in a porcine polytrauma model. No specific reversal agents are routinely available for the direct oral anticoagulants such as dabigatran.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests.

Author: ChoHan-Jin, KangYoon Jung, SungSang Min, AhnSung-Ho, JungYo Han, LeeKyung-Yul, SeoJung Hwa, HanSang Won, ParkJoong Hyun, ChoiHye-Yeon, KwonJee-Hyun, KimWook-Joo, ParkHyung Jong, ChoiJin Kyo, NamHyo Suk, HeoJi Hoe, KimYoung Dae

Stroke severity reduction

This study aimed to evaluate the impact of prothrombin time (PT) and activated partial thromboplastin time (aPTT) on stroke severity in patients with non-valvular atrial fibrillation (NVAF) receiving dabigatran or rivaroxaban. While prior use of direct oral anticoagulants has been linked to reduced stroke severity, this study found no association between PT or aPTT values and stroke severity in patients receiving dabigatran or rivaroxaban at the time of stroke onset.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function.

Author: FusaroMaria, Dalle CarbonareLuca, DussoAdriana, ArcidiaconoMaria Vittoria, ValentiMaria Teresa, AghiAndrea, PashoSabina, GallieniMaurizio

Anticoagulation
Vascular calcification

This study compared the impact of warfarin and dabigatran administration on bone structure and vascular calcification.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.

Author: StaerkLaila, GislasonGunnar H, LipGregory Y H, FosbølEmil L, HansenMorten Lock, LambertsMorten, BondeAnders Nissen, Torp-PedersenChristian, OlesenJonas Bjerring

AF treatment
Gastrointestinal adverse effects

Dabigatran was not associated with upper dyspepsia-like diagnoses or gastrointestinal bleeding requiring hospitalization, and gastroscopy. The risk of subsequent PPI use was increased for OAC-naive dabigatran 110 mg users, and the risk of discontinuation was increased for OAC-experienced dabigatran 150 mg users.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.